发布时间:2019-08-04 00:01 原文链接: ActivationofSrcbyProteintyrosinephosphatasealpha

Progression through the cell cycle is accompanied by activation of the proto-oncogene c-Src, a protein tyrosine kinase. Overexpression of Src leads to tyrosine phosphorylation of multiple protein substrates and cellular transformation. During interphase the Src protein folds back upon itself to stay in the inactive state, with a phophotyrosine residue in one domain at Tyrosine 529 bound by an SH2 domain in the same protein. Activation of c-Src involves protein-tyrosine phosphatase alpha (PTP-alpha, or RPTP-alpha), a transmembrane protein with a cytoplasmic phosphatase domain. A variety of evidence has indicated that PTP-alpha dephosphorylates c-Src at Tyr529, allowing Src to open up and become activated, and that this activation occurs in association with mitosis. To activate Src, PTP-alpha must first open up the folded Src through binding itself to the phosphorylated Src domain, a process blocked by binding of Grb-2 to PTP-alpha at phosphorylated Tyr789. PTP-alpha phosphorylated at Tyr789 also binds to the Src SH2 domain, causing the Src structure to open at Src Tyr529 to become available for dephosphorylation. During mitosis the mitotic kinase Cdc-2 phosphorylates Src, along with other cellular substrates, and in so doing makes Src more prone PTP-alpha dephosphorylation and activation. The activity of PTP-alpha toward Src is also regulated by phosphorylation of PTP-alpha by protein kinase C at serines 180 and 204, releasing the inhibition of PTP-alpha by Grb-2. In the normal cell cycle, Src activity is down-regulated after cell division through dephosphorylation by protein phosphatases and phosphorylation by Csk (C-terminal src kinase) and PTP-alpha dephoshorylation returns the cycle to its interphase condition. The regulation of Src activity during mitosis demonstrates how protein phosphorylation can shifts the delicate equilibrium of molecular interactions and cellular responses.

Contributor:

REFERENCES: Tomas Mustelin and Tony Hunter. Meeting at Mitosis: Cell Cycle-Specific Regulation of c-Src by RPTPa. Sciences stke jan 15, 2002. Xin-Min Zheng and David Shalloway. Two mechanisms activate PTPa during mitosis. The EMBO Journal Vol.20 No.21 pp.6037-49, 2001.


相关文章

科学家将人工智能技术成功用于蛋白质复合物结构预测

蛋白质作为构成人体组织器官的支架和主要物质,在人体生命活动中起着重要作用。蛋白质的相互作用能产生许多效应,如形成特异底物作用通道、生成新的结合位点、失活、作用底物专一性和动力学变化等,细胞的代谢、信号......

布鲁克ALPHAII红外光谱仪亮相BCEIA助力三星堆考古发掘

分析测试百科网讯2021年9月27日-29日,第十九届北京分析测试学术报告会暨展览会(BCEIA2021)在北京•中国国际展览中心开幕。在本届展会上,布鲁克光谱渠道与应用经理王军锋接受了分析测试百科网......

发力癌症分子病理诊断,无锡臻和全资收购TissueofOrigin®

2021年9月9日,无锡臻和生物科技有限公司(以下简称“臻和科技”)与美国VyantBio公司签署TissueofOrigin®(以下简称“TOO®”)全球权益和ZL转让协议,全资收购这款唯一获FDA......

这3个杂志撤回中国学者249篇文章,包含上交、中山等名校

2021年7月20日,JournalofCellularPhysiology及JournalofCellularBiochemistry同时撤回了中国学者49篇文章。从2019年开始,Journalo......

B.1.1.7变异株抑制人体初始免疫反应

B.1.1.7变异株(也被称为Alpha)的迅速传播,可能与它抑制人体初始免疫反应的能力有关。广泛的肺损伤(绿色;人工彩色计算机断层扫描)表明COVID-19患者患有肺炎。一项关于SARS-CoV-2......

AlphaMOS荣获2020年欧洲最佳感官分析解决方案奖

AlphaMOS(巴黎证券交易所-C区-ISIN代码:FR0000062804-ALM),获得了CFI.co杂志颁发的“2020年欧洲最佳感官分析解决方案”奖。CFI.co(CapitalFinanc......

肿瘤治疗的强心剂,中国学者开发肿瘤治疗新策略

磷酸甘油酸突变酶1(PGAM1)通过其代谢活性以及与其他蛋白质(例如α平滑肌肌动蛋白(ACTA2))的相互作用,在癌症代谢和肿瘤进展中起关键作用。变构调节被认为是发现针对PGAM1的高选择性和有效抑制......

阿斯利康SRC抑制剂获美国FDA孤儿药资格,治疗肺纤维化

英国制药巨头阿斯利康(AstraZeneca)近日宣布,美国食品和药物管理局(FDA)已授予saracatinib治疗特发性肺纤维化(IPF)的孤儿药资格。孤儿药是指用于预防、治疗、诊断罕见病的药品,......

llumina宣布推出新型基因分型芯片|支持AllofUs研究计划

2018年12月6日,来自圣迭戈的消息——Illumina公司(纳斯达克股票代码:ILMN)今天宣布推出新型高密度基因分型芯片Infinium™GlobalDiversityArray。这款芯片设计源......

美国企业在受控核聚变领域研究取得进展

据美国《科学》杂志网站近日报道,位于美国加州的聚变能研究公司TriAlpha最近取得了新的突破,有望在国际热核聚变实验反应堆(ITER)采用的大型托卡马克装置之外为受控核聚变能利用找到更为经济的技术路......